Year: All Releases201720162015201420132012 June 27, 2017 Mersana Therapeutics Announces Pricing of Initial Public Offering PDF Version June 5, 2017 Mersana Confirms Clinical Trial Progress on Lead Oncology Program at ASCO 2017 PDF Version April 2, 2017 Mersana Therapeutics Presents Preclinical Data on XMT-1522 Supporting Efficacy and Tolerability PDF Version March 15, 2017 Mersana Therapeutics to Present at Oppenheimer’s 27th Annual Healthcare Conference PDF Version March 9, 2017 Mersana Adds to Antibody Drug Conjugate (ADC) Intellectual Property Portfolio with Issuance of EP Patent PDF Version March 2, 2017 Mersana Presents New Data on Investigational Cancer Antibody Drug Conjugate at American Association of Cancer Research Annual Meeting PDF Version February 27, 2017 Mersana Therapeutics to Present at the Cowen and Company 37th Annual Health Care Conference PDF Version January 6, 2017 Mersana Therapeutics Appoints Andrew A. F. Hack, M.D., Ph. D. to Board of Directors PDF Version December 21, 2016 Mersana Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare Conference PDF Version December 11, 2016 Mersana Therapeutics’ Lead Immunoconjugate Continues to Demonstrate Complete Tumor Regressions in Multiple HER2-Expressing Breast Cancer Tumor Models PDF Version Pagination Current page 1 Page 2 Page 3 Page 4 … Next page Next Last page Last
